A Multi Center Study Testing a New Implant for Adults With Severe Emphysema

NCT ID: NCT07119229

Last Updated: 2025-09-16

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-30
• Study Completion Date: 2027-11-30

Brief Summary

A study taking place at multiple sites in the United States, Europe and Brazil to evaluate how well a new therapy for severe COPD/emphysema works, and how safe it is.

Detailed Description

IAB-2 is an open-label (unblinded), multicenter, prospective trial of the Implantable Artificial Bronchus (IAB) in adults suffering from severe COPD/emphysema. There is no control group or comparator. The study will be conducted at as many as twelve sites in the United States and three sites outside of the US, in the Netherlands, Germany and Brazil.

Conditions

Emphysema or COPD; Emphysema; COPD

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

All subjects will receive study treatment

All subjects will receive treatment with a maximum of 10 Implantable Artificial Bronchus (IABs) which are polymer based stents that can be permanently placed in any diseased lobe of the lungs.

Group Type: EXPERIMENTAL

Implantable Artificial Bronchus

Intervention Type: DEVICE

The Implantable Artificial Bronchus (IAB) is a tapered, flexible and fenestrated polymer-based airway stent that is implanted bronchoscopically using a proprietary delivery system into diseased lungs of patients with emphysema.

Interventions

Implantable Artificial Bronchus

The Implantable Artificial Bronchus (IAB) is a tapered, flexible and fenestrated polymer-based airway stent that is implanted bronchoscopically using a proprietary delivery system into diseased lungs of patients with emphysema.

Intervention Type: DEVICE

Other Intervention Names

IAB

Eligibility Criteria

Inclusion Criteria

1. Signed Informed Consent.

2. Diagnosis of COPD/emphysema.

3. At least 22-years of age.

4. 18 ≤ BMI ≤ 32.

5. 6-minute walk Distance between 100-meters and 400-meters at baseline exam.

6. Stable disease with less than 10-mg prednisone (or equivalent) daily

7. Non-smoking for 4-months prior to screening interview (including tobacco, vaping, marijuana, etc.).

8. FEV1 between 15% and 50% of predicted value at baseline exam.

9. FEV1/FVC <70%.

10. Subject has ≥25% emphysema destruction score in each lung defined by areas of low attenuation <-950 HU, as determined by CT core lab.

11. Subject has homogeneous or heterogeneous emphysema, and at least one lung has a 15% difference between upper and lower lobes in emphysema destruction score (< -950HU) as determined by CT core lab.

12. RV > 175% of predicted value.

13. mMRC score ≥ 2.

Exclusion Criteria

• 1. Currently participating in another clinical study that involves surgery, interventional or pharmaceutical treatment..

2. α-1 Antitrypsin deficiency 3. Women of child-bearing potential. 4. More than 2 COPD exacerbation episodes requiring hospitalization in the last year prior to screening.

5. Any COPD exacerbations requiring hospitalization within 6-weeks of planned intervention.

6. Two or more instances of pneumonia episodes requiring hospitalization in the last year prior to screening.

7. Clinically significant mucus production or chronic bronchitis. 8. Myocardial Infarction or unstable / uncontrolled congestive heart failure within 6-months of screening.

9. Prior lung transplant, LVRS, bullectomy, lobectomy or endoscopic lung volume reduction (ELVR).

10. Clinically significant bronchiectasis. 11. Unable to safely discontinue anti-coagulants or platelet activity inhibitors for 7-days.

12. Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure >45 mm Hg) or evidence or history of cor pulmonale as determined by recent echocardiogram (completed within the last 3-months prior to screening visit). Note: the echocardiogram is not a required screening procedure.

13. Suspected malignant pulmonary nodule or other lung cancer. 14. HRCT collected per CT scanning protocol within the last 6-months of screening date and evaluated by clinical site personnel using 3D segmentation software shows:

1. Large bullae encompassing greater than 30% of either lung

2. Insufficient landmarks to evaluate the CT study using the software as it is intended

3. All lobes are less than 25% parenchyma diseased (< -950 HU) 15. Any cardiac comorbidity which the PI believes would compromise the safety of the patient after an IAB implant.

16. TLC < 100% predicted at screening. 17. DLCO < 15% or > 50% of predicted value at screening. 18. PaCO2 > 50 mm Hg at screening. 19. PaO2 < 45 mm Hg in room air at screening. 20. Plasma cotinine level > 13.7 ng/ml or carboxyhemoglobin (arterial or ear lobe capillary) >2.5% at screening.

21. Current diagnosis of substance abuse disorder. 22. Current diagnosis of any of the following: Major Depressive Disorder (MDD), Schizoaffective Disorder, Schizophrenia, Borderline Personality Disorder, Bipolar Disorder.

23. Any other conditions, which, in the opinion of the Investigator, would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study.

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pulmair Medical, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

George Cheng, MD, PhD.

Role: PRINCIPAL_INVESTIGATOR

Unversity of California San Diego

Central Contacts

VP Clincal Operations

Role: CONTACT

tkruger@pulmair.com

858-369-0000

Clinical Study Manager

Role: CONTACT

mgil@pulmair.com

858-369-0000

Other Identifiers

IAB2-CIP-v01

Identifier Type: -

Identifier Source: org_study_id